Nuclidium AG | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,548 results for “Nuclidium AG”

Trials

View all 352 →

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

49 participants · First posted Nov 17, 2017

No Longer Available

Expanded Access for AG-221

First posted Oct 29, 2018

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

36 participants · First posted Nov 10, 2011

Drugs

View all 383 →

67Cu-based CuNeo therapeutic (NUCLIDIUM)

61Cu-based CuNeo Diagnostic (NUCLIDIUM)

AG-2009

Organizations

View all 285 →

Siemens AG

AbbVie AG

Switzerland

Ferring AG

Switzerland

News

View all 528 →

NUCLIDIUM Secures US Patent Protection for Copper-Based FAP-Targeting Radiotheranostics Platform

NUCLIDIUM's Copper-Based PET Tracer Shows Promise in Phase I/II Trial for Neuroendocrine Tumor Detection

Nuclidium Raises €115 Million to Advance Copper-Based Radiotheranostics for Prostate and Breast Cancer

Page 1 of 155